WHO ICTRP trial
A prospective clinical study of carbidopa in the treatment of platinum-resistant…
ChiCTR2200064102 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2200064102 |
|---|---|
| Public title | A prospective clinical study of carbidopa in the treatment of platinum-resistant neuroendocrine prostate cancer |
| Scientific title | A prospective clinical study of carbidopa in the treatment of platinum-resistant neuroendocrine prostate cancer |
| Primary sponsor | Renji Hospital, School of Medicine, Shanghai Jiao Tong University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 1 |
| Countries | China |
| Conditions | neuroendocrine prostate cancer |
| Interventions | 1:Carbidopa 25 mg/d;2:Carbidopa 75 mg/d;3:Carbidopa 125 mg/d;4:Carbidopa 175 mg/d |
| Registration date | Sep 26, 2022 |
| Target size | 1:3;2:3;3:3;4:3 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: